Multiple Myeloma Drugs Market to grow by USD 6,419.94 million from 2022 to 2027|Growing incidence of multiple myeloma boosts the market growth - Technavio

NEW YORK, July 10, 2023 /PRNewswire/ -- The global multiple myeloma drugs market size is estimated to grow by USD 6,419.94 million from 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 5.9% during the forecast period. North America is estimated to account for 36% of the global market growth. The growing prevalence of various cancer indications, including multiple myeloma and non-Hodgkin's lymphoma, is driving the growth of the regional market. The market in North America is further benefitted from the availability and high sales of approved multiple myeloma drugs. The patent expiry of a major drug brand has resulted in the development of generic versions of the drug by various large- and mid-sized pharmaceutical vendors in the region. This is contributing to the growth of the multiple myeloma drugs market in North America. For more insights on the historic period (2017 to 2021) and forecast market size (2023 to 2027) - Request a sample report

What's New?

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession 
• Global competitiveness and key competitor positions 
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial  - buy the report!

Multiple Myeloma Drugs Market - Segmentation Assessment
Segment Overview
This market report extensively covers market segmentation by therapy (targeted therapy, biologic therapy, chemotherapy, and others), distribution channel (hospital pharmacy, retail pharmacy, and e-pharmacy), and geography (North America, Europe, Asia, and Rest o the World (ROW)). 

• The targeted therapy segment is significant for the growth of the global market's growth during the forecast period. The increasing demand for targeted therapies is driven by the efficacy of the therapy in blocking the action of a substance in myeloma cells that disrupt proteins. This action helps in killing the myeloma cells. Also, the increasing number of drug approvals for the treatment of multiple myeloma is fueling the growth of the segment.

Insights on the market contribution of various segments, including country and region wise historic data (2017 to 2021), and forecast market size (2023 to 2027) - Download a Sample Report

Multiple Myeloma Drugs Market – Market Dynamics
Key factor driving market growth

• The global market for multiple myeloma medications is expanding due to the rising incidence of the disease.
• The rising prevalence of multiple myeloma worldwide is one of the key factors driving the market for multiple myeloma medications.
• Multiple myeloma is the prime target indication for the vendors in the market, as there is a huge opportunity for them.  
• A rise in the number of new instances of myeloma has been observed in the market despite recent improvements in the therapeutic landscape for multiple myeloma.

Leading trends influencing the market 

• The emergence of nanomedicine platforms is a primary market trend. 
• Lipid-based nanoparticles and polymer-based approaches for drug delivery are gaining traction in the market. This is due to the limitations of current technologies.
• Furthermore, the existing technologies need numerous cells to detect the presence of a tumor, whereas, the nanotechnology approach could radically lower this need, allowing much earlier diagnosis and treatment regimes.
• Hence, such trends fuel the market growth during the forecast period.

Major challenges hindering the market growth

• The growing popularity of complementary and alternative medicine challenges the growth of the market.
• The increasing side effects of conventional drugs and individuals seeking CAM (Complementary and alternative medicine) therapies is another major challenge for the market.
• Furthermore, the growing demand for these therapies drives healthcare organizations to undertake research that facilitates the use of CAM therapies for the treatment of multiple myeloma.
• For example, the National Cancer Research Institute has established the Palliative and Supportive Care Clinical Studies Development Group to carry out several studies in the UK.
• Hence, such initiatives are expected to hamper market growth during the forecast period.

Insights on Market Drivers, trends, & Challenges, historic period(2017 to 2021), and forecast period(2023 to 2027)- Request a sample report!

What are the key data covered in this Multiple Myeloma Drugs Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the multiple myeloma drugs market between 2023 and 2027
• Precise estimation of the size of the multiple myeloma drugs market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the multiple myeloma drugs market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of multiple myeloma drugs market vendors

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The compounding pharmacy market size is estimated to grow at a CAGR of 2.18% between 2022 and 2027. The market size is forecast to increase by USD 1,682.04 million. This compounding pharmacy market report extensively covers market segmentation by product (topical medications, oral medications, parenteral medications, and other medications), therapeutic area (pain management, hormone replacement, dermal disorders, and other therapeutic areas), and geography (North America, Europe, Asia, and Rest of World (ROW)). The growing popularity of HRT fueling demand for compounded medications is notably driving market growth. 

According to Technavio's analyst, the proteasome inhibitors market size is expected to be valued at USD 2.20 billion by 2026 with a CAGR of 7.4%. The proteasome inhibitors market has been broadly categorized into the following demographic segmentations including products (VELCADE, KYPROLIS, NINLARO, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). One of the key proteasome inhibitors market trends fueling the market growth is the expanded application.

Table of Contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022 

• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global multiple myeloma drugs market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on Global multiple myeloma drugs market 2017 - 2021 ($ million)

• 4.2 Therapy Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ million)

• 4.3 Distribution Channel Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy

• 6.1 Market segments 
• Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)

• 6.2 Comparison by Therapy 
• Exhibit 32: Chart on Comparison by Therapy
• Exhibit 33: Data Table on Comparison by Therapy

• 6.3 Targeted therapy - Market size and forecast 2022-2027
• Exhibit 34: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%)

• 6.4 Biologic therapy - Market size and forecast 2022-2027
• Exhibit 38: Chart on Biologic therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Biologic therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Biologic therapy - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Biologic therapy - Year-over-year growth 2022-2027 (%)

• 6.5 Chemotherapy - Market size and forecast 2022-2027
• Exhibit 42: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)

• 6.6 Others - Market size and forecast 2022-2027
• Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 6.7 Market opportunity by Therapy 
• Exhibit 50: Market opportunity by Therapy ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments 
• Exhibit 51: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 52: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel 
• Exhibit 53: Chart on Comparison by Distribution Channel
• Exhibit 54: Data Table on Comparison by Distribution Channel

• 7.3 Hospital pharmacy - Market size and forecast 2022-2027 
• Exhibit 55: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)

• 7.4 Retail pharmacy - Market size and forecast 2022-2027
• Exhibit 59: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)

• 7.5 E-pharmacy - Market size and forecast 2022-2027
• Exhibit 63: Chart on E-pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 64: Data Table on E-pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Chart on E-pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 66: Data Table on E-pharmacy - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Distribution Channel
• Exhibit 67: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 69: Chart on Market share by geography 2022-2027 (%)
• Exhibit 70: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 71: Chart on Geographic comparison
• Exhibit 72: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 81: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 89: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.9 China - Market size and forecast 2022-2027
• Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.10 Canada - Market size and forecast 2022-2027
• Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.11 UK - Market size and forecast 2022-2027
• Exhibit 105: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 106: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 107: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 108: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 109: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers 

• 10.2 Market challenges 

• 10.3 Impact of drivers and challenges 
• Exhibit 110: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends 

11 Vendor Landscape

• 11.1 Overview 

• 11.2 Vendor landscape 
• Exhibit 111: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 112: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 113: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 114: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 115: Matrix on vendor position and classification

• 12.3 Abbott Laboratories 
• Exhibit 116: Abbott Laboratories - Overview
• Exhibit 117: Abbott Laboratories - Business segments
• Exhibit 118: Abbott Laboratories - Key news
• Exhibit 119: Abbott Laboratories - Key offerings
• Exhibit 120: Abbott Laboratories - Segment focus

• 12.4 AbbVie Inc. 
• Exhibit 121: AbbVie Inc. - Overview
• Exhibit 122: AbbVie Inc. - Product / Service
• Exhibit 123: AbbVie Inc. - Key offerings

• 12.5 Amgen Inc. 
• Exhibit 124: Amgen Inc. - Overview
• Exhibit 125: Amgen Inc. - Product / Service
• Exhibit 126: Amgen Inc. - Key offerings

• 12.6 Bristol Myers Squibb Co. 
• Exhibit 127: Bristol Myers Squibb Co. - Overview
• Exhibit 128: Bristol Myers Squibb Co. - Product / Service
• Exhibit 129: Bristol Myers Squibb Co. - Key offerings

• 12.7 Daiichi Sankyo Co. Ltd. 
• Exhibit 130: Daiichi Sankyo Co. Ltd. - Overview
• Exhibit 131: Daiichi Sankyo Co. Ltd. - Business segments
• Exhibit 132: Daiichi Sankyo Co. Ltd. - Key news
• Exhibit 133: Daiichi Sankyo Co. Ltd. - Key offerings
• Exhibit 134: Daiichi Sankyo Co. Ltd. - Segment focus

• 12.8 F. Hoffmann La Roche Ltd. 
• Exhibit 135: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 136: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 137: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 138: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 139: F. Hoffmann La Roche Ltd. - Segment focus

• 12.9 GlaxoSmithKline Plc 
• Exhibit 140: GlaxoSmithKline Plc - Overview
• Exhibit 141: GlaxoSmithKline Plc - Business segments
• Exhibit 142: GlaxoSmithKline Plc - Key offerings
• Exhibit 143: GlaxoSmithKline Plc - Segment focus

• 12.10 Johnson and Johnson 
• Exhibit 144: Johnson and Johnson - Overview
• Exhibit 145: Johnson and Johnson - Business segments
• Exhibit 146: Johnson and Johnson - Key news
• Exhibit 147: Johnson and Johnson - Key offerings
• Exhibit 148: Johnson and Johnson - Segment focus

• 12.11 Merck and Co. Inc. 
• Exhibit 149: Merck and Co. Inc. - Overview
• Exhibit 150: Merck and Co. Inc. - Business segments
• Exhibit 151: Merck and Co. Inc. - Key news
• Exhibit 152: Merck and Co. Inc. - Key offerings
• Exhibit 153: Merck and Co. Inc. - Segment focus

• 12.12 Novartis AG 
• Exhibit 154: Novartis AG - Overview
• Exhibit 155: Novartis AG - Business segments
• Exhibit 156: Novartis AG - Key offerings
• Exhibit 157: Novartis AG - Segment focus

• 12.13 Pfizer Inc. 
• Exhibit 158: Pfizer Inc. - Overview
• Exhibit 159: Pfizer Inc. - Product / Service
• Exhibit 160: Pfizer Inc. - Key news
• Exhibit 161: Pfizer Inc. - Key offerings

• 12.14 PharmaMar SA 
• Exhibit 162: PharmaMar SA - Overview
• Exhibit 163: PharmaMar SA - Business segments
• Exhibit 164: PharmaMar SA - Key news
• Exhibit 165: PharmaMar SA - Key offerings
• Exhibit 166: PharmaMar SA - Segment focus

• 12.15 Sanofi SA 
• Exhibit 167: Sanofi SA - Overview
• Exhibit 168: Sanofi SA - Business segments
• Exhibit 169: Sanofi SA - Key news
• Exhibit 170: Sanofi SA - Key offerings
• Exhibit 171: Sanofi SA - Segment focus

• 12.16 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings

• 12.17 Teva Pharmaceutical Industries Ltd.
• Exhibit 176: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 177: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 178: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 179: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 180: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report 

• 13.2 Inclusions and exclusions checklist
• Exhibit 181: Inclusions checklist
• Exhibit 182: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 183: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 184: Research methodology
• Exhibit 185: Validation techniques employed for market sizing
• Exhibit 186: Information sources

• 13.5 List of abbreviations 
• Exhibit 187: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio